References
- Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol 2018; 38:435–42
- Cheung CHK, Barratt J. IgA nephropathy: Clinical features and diagnosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. 2023
- McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26:414–30
- Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368:2402–14.
- Suzuki H, Kiryluk K, Novak J et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol 2011; 22:1795–803
- Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018 Oct;94(4):674–681
- Pitcher D, Braddon F, Hendry B et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol 2023; 18:727–38
- Moriyama T, Tanaka K, Iwasaki C et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single centre in Japan. PLoS One 2014;9:e91756.
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4S): S1–S276.
- Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new international risk- prediction tool in IgA nephropathy. JAMA Intern Med. 2019; 179:942–952
- Rovin BH, Adler SG, Barratt J et al. Executive summary of the KDIGO 2021 Guideline for the management of glomerular diseases. Kidney Int 2021; 100:753–79
- Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016; 387:435–443
- Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016; 67:728–741
- Heerspink HJL, Stefansson BV, Correa-Rotter R et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383:1436–46
- The E-KCG, Herrington WG, Staplin N et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023; 388:117–27
- Wheeler DC, Toto RD, Stefansson BV et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int 2021; 100:215–24
- EMPA-KIDNEY Collaborative Group. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial. Nephrol Dial Transplant 2022; 37:1317–29
- Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3:CD003965
- Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373:2225–36
- Lv J, Wong MG, Hladunewich MA et al. Effect of oral methyl- prednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2022; 327:1888–98
- Hou FF, Xie D, Wang J et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open 2023;6:e2254054
- Stefan G, Mircescu G. Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail 2021; 43:1520–7
- Duan J, Liu D, Duan G et al. Long-term efficacy of tonsillectomy as a treatment in patients with IgA nephropathy: a meta- analysis. Int Urol Nephrol 2017; 49:103–12
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219–2229.
- Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet 2023
- Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int 2022
- Kiryluk K. GWAS defines pathogenic signaling pathways and prioritizes 5 drug targets for IgA nephropathy. MedRxIV 2021.
- Zhai YL, Zhu L, Shi SF, et al. Increased APRIL Expression Induces IgA1 Aberrant Glycosylation in IgA Nephropathy. Medicine (Baltimore) 2016; 95:e3099
- Barratt J HB, Schwartz BS, Sorensen B, Roy SE, Stromatt CL, MacDonald M, Endlsey AN, Lo J, Glicklich A, King AJ: Pharmacodynamic and Clinical Responses to BION-1301 in Patients with IgA Nephropathy: Initial Results of a Ph1/2 Trial. In ASN Kidney Week 2021, 2021
- Mathur M, Barratt J, Suzuki Y, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep 2022; 7: 993–1003.
- Cheung CK, Dormer JP, Barratt J. The role of complement in glomerulonephritis - are novel therapies ready for prime time? Nephrol Dial Transplant 2022
- Bruchfeld A, Magin H, Nachman P, et al. C5a receptor inhibitor avacopan in immunoglobulin A nephropathy-an open-label pilot study. Clin Kidney J 2022; 15: 922–928
- Lafayette RA, Rovin BH, Reich HN, et al. Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney Int Rep 2020; 5: 2032–2041
- Barratt J RB, Zhang H, Kashihara N, Maes B, Rizk D, Trimarchi H, Sprangers B, Meier M, Kollins D, Wang W, Magirr A, Perkovic V. POS-546 Efficacy and Safety of Iptacopan in IgA Nephropathy: Results of a Randomized Double-Blind Placebo-Controlled Phase 2 Study at 6 Months. Kidney International Reports 2022; 7.
- Patrick J Gleeson, Michelle M O'Shaughnessy, Jonathan Barratt, IgA nephropathy in adults treatment standard, Nephrology Dialysis Transplantation, Volume 38, Issue 11, November 2023, Pages 2464–2473